



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

MMAE-d₈

Cat. No.:	HY-15162A
CAS No.:	2070009-72-0
Molecular Formula:	C ₃₉ H ₅₉ D ₈ N ₅ O ₇
Molecular Weight:	726.03
Target:	Microtubule/Tubulin; ADC Cytotoxin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related
Storage:	Powder -20°C 3 years 4°C 2 years

* The compound is unstable in solutions, freshly prepared is recommended.



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (137.74 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM		1.3774 mL	6.8868 mL	13.7735 mL
		5 mM		0.2755 mL	1.3774 mL	2.7547 mL
		10 mM		0.1377 mL	0.6887 mL	1.3774 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.44 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.44 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil					
	Solubility: ≥ 2.5 mg/mL (3.44 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	MMAE-d ₈ is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
IC ₅₀ & Target	Auristatin
In Vitro	Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-molecule payloads. ADCs are generated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and the intracellular concentration of released MMAE correlated with in vitro ADC-mediated cytotoxicity independent of target expression or drug:antibody ratios. LC-MS is used to measure the

concentration of MMAE in a parallel cohort of L-82 tumors with an identical treatment regimen. Although tumor volume is not different among treatment groups 3 days after dose, the intratumoral MMAE measurement reveals two patterns. First, intratumoral MMAE concentration increases proportionally to the ADC dose, which corresponds to stronger antitumor activity. Second, the intratumoral MMAE concentration obtained from treatment with both cOKT9-vcMMAE and cAC10-vcMMAE is similar at each dose, consistent with the observation that tumor responded similarly to these two ADCs^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Intratumoral MMAE concentrations consistently correlates with the extent of tumor growth inhibition in tumor xenograft models. IHC analysis reveals that nonbinding control-treated tumors consist of both CD30⁺ and CD30⁻ cells, presumably because they do not kill either CD30⁺ or CD30⁻ Karpas 299 cells. Only CD30⁻ cells are found in cAC10-vcMMAF-treated tumors, illustrating that cAC10-vcMMAF eliminates most CD30⁺ cells. Interestingly, the two tumors that relapses from cAC10-vcMMAE treatment are also found to be CD30⁻ by the end of study, indicating a small fraction of CD30⁻ cells might have escaped from bystander killing in these two remaining tumors^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Kinase Assay ^[1]

Cell pellets are collected 24 hours after ADC treatment. Cell count, diameter, and circularity are determined on Vi-Cell Counter. MMAE extraction and quantification method is performed. Briefly, tumors or cell pellets are homogenized with methanol and acetonitrile containing internal standard (d⁸-MMAE for MMAE detection and ¹³C-MMAF for MMAF detection). The homogenates are centrifuged at 10,000 rpm to precipitate protein and protein-bound payloads. The supernatant is then subjected to solid phase extraction, and signals of MMAE and MMAF are detected by LC-MS^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Pharm Anal. 24 November 2021.
- Mol Cancer Ther. 2023 Jan 31;MCT-22-0440.
- AAPS J. 2021 Apr 15;23(3):56.
- Drug Metab Dispos. 2017 Nov;45(11):1120-1132.
- J Pharm Biomed Anal. 2024 Jun 19;248:116318.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Li F, et al. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Res. 2016 May 1;76(9):2710-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA